

Dab/Tram (dabrafenib and trametinib) ROAR

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Dab/Tram (dabrafenib and trametinib) ROAR

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Endocrine Tumours  
 Therapeutic Indication: Patients with locally advanced or metastatic ATC with BRAF V600E mutation and with no satisfactory locoregional treatment options  
 Experimental Arm: Dab/Tram (dabrafenib and trametinib)  
 Control Arm: Single arm

